The dog is a commonly used animal model by virtue of its size, well-characterized physiology, and ease of handling. For these reasons and others, dogs are also useful in pharmacokinetic and metabolism studies during the development of both human and veterinary pharmaceutical products. In comparison with humans, or with other animals, dogs have some unique physiologic attributes that can affect the disposition of drugs. Species differences in gastrointestinal physiology, metabolism, renal function, and protein binding can affect the correlation of the pharmacokinetics and toxicology of dogs with those of other species. With the use of relevant examples, this article will provide an introduction to characteristics of dog physiology and their impact on pharmacokinetics, metabolism, drug disposition, toxicity, and dose selection.
INTRODUCTION
Much of the data collected about a drug prior to its use in either humans or veterinary patients is obtained from laboratory animal species. Although the use of these species provides invaluable information regarding the efficacy, pharmacokinetics, and toxicology of the putative product, there can be significant gaps between the data derived from species that are different than the target patient population. The dog has long been used as a test animal in these preclinical studies, and the relevant aspects of dog physiology have been explored in an effort to better understand how the dog both resembles and differs not only from other species used in pharmaceutical research but also from the species for which most of these products are developed: man. The unique aspects of canine physiology have a wide-ranging impact on the pharmacokinetics, metabolism, and, consequently, the toxicity of xenobiotics. This article is intended as a survey of those physiologic processes in dogs that may be similar or distinct from other species, and the potential effects these differences can have on the pharmacokinetics and metabolism of xenobiotics. The broad nature of this topic prevents the development of a thorough discussion of all relevant studies and data.
Gastrointestinal
Following oral administration, the first environment encountered by a xenobiotic is the stomach. The interaction between the compound, its dosage form, and the gastric milieu can be complex. Gastric pH can affect the ability of an acidic or basic drug to dissolve in gastric fluids. This dissolution is an important step in the subsequent absorption of the compound. Although the stomach of monogastric mammals behaves similarly across species, there are some characteristics of acid secretion in the dog stomach that can affect the pharmacokinetics of drug compounds.
Whereas the fasting pH of the stomach in dogs is similar to humans and other mammals [1.5-2.0, (29) ], basal acid secretion in dogs is lower than that of humans, pigs, or monkeys (Table 1 ). In addition, the canine gastric pH is quite variable and may be elevated to levels similar to the pH of the duodenal contents (18) . This variability can lead to considerable interanimal variability in drug dissolution and absorption, particularly for drugs whose solubility is strongly pH-dependent. A study of thiamine disulfide absorption in beagles provides an example of the impact of this variability. In this study, fasted dogs were administered a tablet dose of thiamine followed by measurement of drug absorption and gastric pH. The data indicated that dogs with low gastric pH had significantly greater absorption of thiamine. Gastric pH ranged from approximately 3-6 and absorption (as measured by area under the plasma concentration vs time curve) varied from ∼5-50 hr-ng/ml (3) .
Following feeding, the dog stomach has a high capacity for acid secretion. This secretory capacity can act to prevent the post-prandial buffering action of food observed in many other species. Thus, the fed stomach pH in dogs may not increase dramatically immediately following feeding (18) .
Gastric mucin, a highly hydrophilic glycoprotein gel with numerous anionic polysaccaride subunits, may affect the ability of the gastrointestinal tract to neutralize stomach acid and the rate of gastrointestinal transit of certain drug dosage forms. In addition, this gelatinous layer is known to support a pH gradient with a more basic environment existing at the level of the surface of the gastric mucosa (43) . This gradient increases the complexity of the barrier in respect to its permeability to xenobiotic agents. Dogs and rats have been found to have a thicker gastric mucous layer than humans (∼400-700 µm vs ∼25-300 µm) suggesting that the influence of this mucous on drug absorption may be more pronounced in dogs and rats (1, 30) .
As most drugs undergo the majority of their absorption in the small intestine, gastric motility and the rate of gastric emptying can affect not only the extent of oral absorption, but also the absorption rate. In the fasted state, the stomach 18 TIBBITTS TOXICOLOGIC PATHOLOGY (18, 21, 25, 29, 65) .
alternates between a resting state and contractions that act to move nonliquid gastric contents into the small intestine. A subset of these contractions, Phase III contractions, are important in the transfer of nondisintegrated solid dosage forms (tablets, capsules) to the small intestine (18) . Humans and all laboratory mammals exhibit this pattern, but the frequency and duration of the contractions varies between species. Comparisons of fasted dogs and humans have shown significant similarity in the patterns of gastric contractions (Table 2) (18). An interesting example of the importance of gastric motility is seen in a study by Lipka et al (39) examining the absorption of celiprolol. Oral doses of celiprolol were administered to fasted dogs fitted with monitors of gastric motor activity. Dogs administered drug during Phase I of the gastric motility cycle (a resting phase) had a profound lag time before drug absorption while administration of drug during Phase III (an active contraction phase) facilitated rapid movement of drug to the duodenum for immediate absorption.
With feeding, gastric motility patterns change dramatically. The character of the meal will affect the pattern, as well. Oral intake of a nonnutritive liquid will not disturb the fasting patterns of the stomach. However, ingestion of a nutritive liquid will cause a slowing of gastric emptying by approximately 5-fold in both humans and dogs. The addition of solid food slows liquid emptying even further. The rate of liquid emptying is affected by meal size and composition, but it has been reported that dogs generally exhibit slower emptying times than humans (18) . This difference is important for drugs that may be delivered with food and undergo dissolution in the stomach. Like liquids administered with solids, the rate of emptying of solids is dependent on meal size and composition, and dogs have slower rates of emptying.
Following feeding, there is a delay in the return to the fasting motility pattern. This delay appears to be longer in dogs than humans and may, in dogs, cause a relative delay in the absorption of nondissolvable solid dosage forms administered with food.
As mentioned earlier, drug absorption occurs predominantly in the small intestine. The degree of absorption is dependent on the physicochemical characteristics of the drug, the intestinal environment, and the time spent in the small intestine. Small intestinal pH is typically lowest at the proximal end and increases along its length. pH in the duodenum is strongly influenced by gastric acid and pancreatic bicarbonate secretions. In the fasted state, the dog has a bicarbonate secretion rate that is greater than the basal gastric acid secretion rate. In humans, the reverse is true. As a result, fasted dogs have a slightly higher (1-2 pH units) small intestinal pH than humans (18) . In fed dogs, the pH of the duodenal contents tends to decrease to a greater extent than in humans due to the dogs' high capacity for postprandial acid secretion (18) .
These differences in gastrointestinal pH are likely to have the most influence on drugs whose pKa or solubility have transitions in the range of pH 3-7. Comparisons of the small intestinal pH of dogs with other monogastric mammals show that the dog is similar to these species [±0.5 pH units (29) ]. The importance of gastric and duodenal pH is nicely illustrated by the absorption of L-735,524 (indinavir, an HIV protease inhibitor) in rats and dogs. L-735,524 is soluble at ∼60 mg/ml at pH 3.5 and at <0.03 mg/ml at pH 5.0. Administration to fasted dogs of L-735,524 in citrate (pH 2.5) provided a 4-fold improvement in oral bioavailability when compared to a methylcellulose formulation, presumably due to improved solubility provided by the citrate solution in a species with low basal gastric acid secretion. Administration of the drug in citrate to rats did not improve bioavailability since rats, with a high basal acid secretion, are capable of adequate solubilization of the drug without the assistance of citrate (35) .
The absorption of lipid-soluble drugs can be improved with the addition of bile salts. These salts act to improve the dissolution of these lipophilic drugs (44) , thus making them more available for absorption. Dogs secrete bile salts at a high rate, in comparison with monkeys, rats, and humans (Table 3) . Disparity in bile salt secretion could provide the dog with an increased capacity for absorption of lipophilic compounds. Bile salts were found to provide significantly better absorption of Cyclosporine A, a highly lipophilic drug, in dogs (22) .
The ability of the small intestine to absorb compounds is dependent not only on drug dissolution but also on the time that drug spends in that organ. In dogs, transit time through the small intestine is particle size dependent with larger particles requiring more time for transit. Transit time in fasted dogs is approximately 2-fold shorter than in humans (111 vs 238 minutes) and shows much greater variability (18) . This would contribute to a lower and more variable absorption in dogs than in humans, independent of the other factors affecting absorption.
At the cellular level, there may be species differences in the integrity of the intestinal barrier and its ability to allow permeation of xenobiotics. Paracellular permeation is an important route for oral absorption of hydrophilic molecules and is governed, in part, by molecular weight. A study by He et al (23) used the oral absorption of polyethylene glycol (PEG) oligomers (molecular mass 282-1295 Daltons) in dogs, rats, and humans. Their data indicate that oral bioavailability of the PEG oligomers decreased with a nearly log-linear relationship to molecular mass in all species. However, the dog had much greater overall bioavailability for PEG oligomers and the log-linear decline in permeability occurred at a higher molecular mass. In additional studies of the morphometry of rat and dog intestine, the authors suggested that the species differences in absorption of PEG may be related to differences in the size and density of paracellular pathways. The interrelationship of the physiologic characteristics of the canine gastrointestinal tract and those of a particular compound can be difficult to unravel. Ultimately, the question is which species has absorption that is most representative of humans. Chiou et al (10) addressed this question by comparing the oral absorption of 43 compounds in dogs and humans. The compounds varied greatly in physicochemical characteristics and included bases, acids, zwitterions, and neutral compounds. Dogs showed a poor correlation (r 2 = 0.51) with humans. The authors found that drugs that were well absorbed in humans were likely to be also be well absorbed in dogs. However, the converse may not be true: drugs well absorbed in dogs may not exhibit the same characteristics in humans. In contrast to dogs, a similar study showed that rats had a much strong correlation in absorption with humans (r 2 = 0.97) (9) . Whereas the physiologic differences between species remain to be fully appreciated, the rat may provide a better prediction of human drug absorption than dogs. The greater absorption commonly exhibited by dogs may, however, make the dog particularly useful for preclinical toxicology studies by providing higher systemic drug exposure allowing a better evaluation of the toxic response.
Hepatic Metabolism
Hepatic metabolism of xenobiotics is influenced by several factors, including blood flow through the liver, plasma protein binding of the drug, and the metabolic capacity of hepatic enzymes. Typically, organ blood flow per unit of body weight (ml/min/kg) in most species decreases with increased body size. The dog is consistent with the allometry describing this relationship (35) . As in other species, the dog's liver contributes ∼3% of its body weight. The dog does have a slightly higher percentage of its cardiac output directed through the liver (∼30%) when compared with other species (18% rat, 23% humans) (7) .
Cytochromes P450 (CYP450) perform catabolic reactions on a wide variety of endogenous and exogenous compounds. The amount of CYP450 enzyme per mg of liver protein is similar in dogs and humans, but less than that of rats, monkeys, and guinea pigs (59) . The overall content of CYP450 in the liver, however, is not predictive of a species' ability to metabolize any single compound. Dogs are known to possess CYP450 enzymes from the same subfamilies as those present in other species (CYP450s 1, 2, 3). Indeed, CYP450 isozymes unique to the dog have been identified (eg, 1A1/2, 2B11, 2C21, 2C41, 2D15, 3A12, 3A26). Comparisons of the sequence of canine isoforms with homologues of other species have shown a high degree of amino acid sequence identity, (6) but the similarities in sequence have not always predicted similarities in enzymatic characteristics. In an ef-fort to better understand the metabolic profile of the canine CYP450s, numerous studies have been conducted comparing the activity and specificity of dog CYP450 isozymes with those of other species (6, 8, 56, 59) . An overarching conclusion in many of these studies is that there are significant differences in the metabolic activities of dog CYP450s when compared with other species. What is not well understood is the cause of these differences. Most of these studies employed enzyme substrates, or inhibitory antibodies, specific for the CYP450s of rats or humans. Unfortunately, we currently have a limited understanding of the substrate specificities of canine CYP450 enzymes. It is possible that substrates that are metabolized by one CYP450 enzyme in humans or rats are, in dogs, metabolized by several. In addition, the specificity of non-canine inhibitory antibodies against unique canine CYP450s is also not well established (59) . For example, human CYP450 3A4 antibodies were unable to inhibit the in vitro metabolism by recombinant canine CYP3A12 of disopyramide (67) , while inhibition of disopyramide was successfully achieved with antibodies generated to CYP3A12. Issues such as these complicate the interpretation of studies using human or rat CYP450 probes, or inhibitory antibodies, for the purpose of comparing the metabolic capacities and specificities of CYP450 isozymes between species. Despite of these limitations, these studies have been valuable in building an understanding of species differences and may allow a general comparison of the metabolic profiles of different species. Indeed, there have been some notable successes in interspecies comparisons Zhang et al (67) showed that mono-Ndealkylation of disopyramide was CYP450 3A-mediated in dogs and humans and that inhibition of this metabolism could be achieved in both species by ketoconazole and troleandomycin. Dogs, in contrast to humans, exhibit stereoselective metabolism of disopyramide. CYP2D15 in dogs metabolizes substrates similar to those of human CYP2D6 (dextromethorphan, bufuralol). However, inhibition of these enzymes by quinidine and quinine differs substantially between species (51) with the dog showing inhibition similar to that seen in rats. Work by Eberhart showed a tremendous species diversity in both the ability to metabolize digitoxin and the resultant metabolites (19) . Another illustrative case is that of CYP450 2B11 in dogs. CYP2B11 is unique to dogs and comprises ∼20% of the total hepatic CYP450 content. Comparisons of the metabolism of testosterone by purified 2B11 with that of homologues from other species showed significant differences in not only the rate of metabolism, but in the metabolites formed (46) . It is likely that findings similar to this will show such differences in other subfamilies of CYP450s. Thus, until the most important canine CYP450 enzymes have been isolated, purified, and their substrate specificities characterized, comparisons and extrapolations between the dog and other species will remain tenuous.
In toxicokinetic studies with repeated dosing, issues of metabolic induction are commonly encountered. Such induction can affect the pharmacokinetics of the administered drug in addition to the pharmacokinetics of some co-administered drugs. Dogs, like other toxicologic species, have shown induction of hepatic enzymes in response to chronic administration of xenobiotics. As might be expected, species similarities and differences in enzyme induction have been described. Studies in dogs have shown that induction of metabolism 20 TIBBITTS TOXICOLOGIC PATHOLOGY occurs in response to compounds (eg, Dexamethasone, phenobarbital, beta-naphthoflavone) known to cause induction in other species (2, 26, 27, 33, 41) . However, the CYP450 isozymes that are induced and their level of induction can exhibit species differences. Nishibe et al (45) showed that rifampin induced CYP3A12 in dogs in a manner similar to that seen with CYP3A4 in humans, while rats showed no induction (41) . Dexamethasone, an inducer of CYP3A4 in humans, was a poorer inducer of CYP3A activity in dogs (41) . A comparison of the induction of probe substrate metabolism in rats and dogs using nine compounds from 5 pharmacological classes found general agreement in the inductive potential of these compounds in both species (2) . Significant qualitative differences between rats and dogs were noted, supporting the assertion that drug oxidation, and its induction, can vary considerably among species. These studies, and others, have provided valuable information in regard to understanding the interspecies relationships in metabolic enzyme induction.
In addition to interspecies differences in metabolism, there has been some study of polymorphic differences in metabolism within canines. Court et al (13) described differences in the microsomal metabolism of propofol between greyhounds and beagles with beagles having significantly greater propofol hydroxylase activity than greyhounds. In a study of celecoxib metabolism in 242 beagles, two distinct populations were identified that differed 10-fold in their capacity to metabolize this drug (48) . This difference in metabolism was paralleled by substantial differences in the pharmacokinetics of celecoxib between the populations. Approximately 45% of the beagles were considered extensive metabolizers with no sex-difference in distribution. The cause of this polymorphism could not be determined definitively. Work by Blaisdell et al (5) showed that the gene coding for CYP2C41, an isozyme unique to dogs, was present in only 14% of the livers of 28 dogs studied (mixed breed and beagles). It is apparent that even a seemingly homogenous population of beagles may exhibit metabolic differences that can result in interindividual variability in pharmacokinetics and toxicity.
The presence of metabolizing enzymes in the intestinal wall can also affect the pharmacokinetics of drugs. Oral pretreatment or coadministration of bergamottin (a furanocoumarin derived from grapefruit juice) resulted in a >20fold increase in oral diazepam exposure in dogs (53) . Intravenous administration of bergamottin also resulted in an increase in oral diazepam exposure. Chronic treatment with bergamottin was found to induce intestinal CYP3A12 activity and to inhibit hepatic CYP3A12 activity. These findings contrast those reported in humans and rats following oral administration of grapefruit juice. The continued study of the impact of intestinal metabolism on the bioavailability of orally administered compounds in dogs may allow for an improved understanding of the pharmacokinetic differences between dogs and other species.
While our understanding of the P450-mediated metabolism of xenobiotics in dogs is improving steadily, knowledge of the Phase II metabolic processes in dogs seems less well developed. Dogs are known to be capable of the Phase II processes common to other mammalian species (glucuronidation, sulfation, N-acetylation, etc). The substrate specificity and capacity of these processes in dogs, in com-parison with other species, is not well understood. One of the more extensively studied pathways is N-acetylation, catalyzed by N-acetyltransferase. Dogs have also been shown to be incapable of N-acetylation of some arylamine compounds (40) . This has led to the conclusion that dogs lack the enzyme family responsible for N-acetylation of these compounds (12) . This was confirmed in a study showing that rats and mice, but not dogs, were capable of the N-acetylation of zafirlukast (54) . Dogs do, however, possess a low capacity for acetylating cyanamide (60) and were also shown to have the capacity for N-acetylation of cilastatin greater than humans, but a poorer capacity for the N-acetylation of others substrates such as sulfanilamide (37) . Studies such as these have led to the suggestion that the canine N-acetyltransferase may possess a different substrate specificity than other species (60) . An excellent review by Chiu and Huskey discusses species differences in the N-glucuronidation of numerous classes of chemical compounds (11) . Recently, progress has been reported in the characterization of canine sulfotransferase enzymes, revealing structural and substrate similarities to those of human, rat, and mouse (62, 63) . From these studies it is clear that the enzyme specificity and capacity of Phase II processes, like those of CYP450s, vary between species and that these differences can have a dramatic impact on the expression of the pharmacokinetics and toxicity of xenobiotics.
Hepatic metabolic capacity in dogs undergoes dramatic changes with maturation. In vitro studies of the metabolism of caffeine and phenytoin showed that the metabolic rate increased from age 1 week until 15 weeks before declining to adult levels at 150 weeks (61) . Other substrates showed an increase in metabolism with age, reaching a peak by 15 weeks with little or no decrease by 150 weeks of age. These changes in metabolic rate with maturation occurred without concomitant changes in hepatic CYP450 concentrations. These data were consistent with those of Kawalek (31) who also showed no change in the mean hepatic CYP450 content in pre-weaned, immature, adult, and geriatric dogs. Probe substrates used by Kawalek to measure CYP450 activity showed no differences between immature (18-52 weeks of age) and adult (59-237 weeks of age) dogs, but dogs older and younger had some differences in activity. Such maturational changes in metabolic activity can have a significant impact on bioavailability and other pharmacokinetic parameters. This was demonstrated with felbamate, where puppies had a higher hepatic metabolic activity resulting in poorer oral bioavailability when compared to adults (66) . Changes in Phase II activity with age were demonstrated by a continual increase in activity throughout life with geriatric dogs having 3-fold higher activity than preweaned puppies (31) . One should be mindful of these changes in hepatic metabolic activity with age when considering studies using immature and geriatric dogs.
Biliary Secretion
Biliary elimination of drugs is of particular importance when the molecular weight of the drug or its metabolites is greater than 300 Da (35) . Other factors that impact the degree of biliary elimination of a compound include polarity and charge. Dogs are considered good biliary excretors, as are mice and rats, yet humans, rabbits, and monkeys are considered less capable excretors (35) . These species differences appear to diminish when the molecular weight of the excreted compound is greater than 700 Da.
Renal
The rate of renal excretion is a function of three renal processes with a relationship shown in equation 1.
Rate of Excretion
The rate of filtration of a drug is related to the amount of drug free in the plasma (not bound to plasma proteins) and the glomerular filtration rate (equation 2).
Rate of Filtration
where C u = unbound concentration of drug in plasma. The glomerular filtration rate (GFR) is dependent on several physiologic factors including renal blood flow [∼15-20% of cardiac output in most species (7) ], and glomeruli/kg (35) . Because cardiac output/kg and number of glomeruli/kg decrease with increasing body weight, it is not surprising that GFR would follow a similar pattern (Table 4) .
For renally excreted compounds not bound to plasma proteins, and not subject to reabsorption or secretion, the renal excretion rate is related to the allometric relationship of GFR with body weight (equation 3).
GFR ∼ BW 0.75 where BW = body weight.
(
The renal excretion of the nucleoside analogue 1-β-Darabinofuranosylcytosine (Ara-C) in several species was found to be correlated to body weight (exponent = 0.8) (15) . The slope of this relationship was very similar to the slope relating inulin clearance, an exclusively glomerular process, to species body weight. Thus, renal excretion of such compounds decreases (on a per kg basis) with increasing animal size; and the dog appears to obey this relationship (20) .
Renal filtration is, however, only a part of the equation defining renal elimination. Renal tubular secretion is mediated by active transport systems specific for acids and bases. Species similarities (24, 64) and differences (24, 47, 57, 58) in renal secretion have been found to exist. Renal tubular reabsorption is the third component of renal excretion and can be either an active or passive process. The degree of absorption is dependent on numerous properties of the molecule (weight, polarity, ionization, plasma protein binding capacity) (52) , and that of the urine and plasma. Differences in diet between species can affect urine pH and consequently the ionization of molecules in the urine. For example, carnivores tend to have urine with a more acidic pH and may re-absorb basic compounds less thoroughly than herbivores. Again, as seen with other renal excretory processes, species differences in reabsorption can occur (28, 57) . Despite the complex interplay of the components of the renal excretory process, several investigators have been successful in performing allometric scaling using the renal excretion parameters of several species, including dogs. In these cases, the renal excretion parameters in the dog correlated well with those of other species (24, 32, 55, 64) . However, caution is advised even when studying the renal excretion within a single class of molecules. The quinolone antibiotics have been shown to exhibit both species and compound dependent differences in absorption and secretion with little correlation (57) . Certainly, the best recipe for success in extrapolating between species is achieved with a detailed understanding of the physicochemical properties of the drug and the renal physiology of the animal species.
Protein Binding
The binding of drugs to plasma proteins can affect numerous pharmacokinetic parameters, in addition to influencing the degree of pharmacologic effect. Extensive plasma protein binding can decrease the systemic clearance of drugs that have a low intrinsic hepatic clearance rate, decrease the ability of drugs to pass into the glomerular filtrate of the kidney, and influence the volume of drug distribution. For many drugs, the pharmacodynamic effects are dependent on the concentration of unbound drug in the plasma. Consequently, species specificity in plasma protein binding can result in significant interspecies differences in both pharmacokinetics and pharmacodynamics. The extent of protein binding in any species is often dependent on the concentration of the binding protein in plasma and the ability of that protein to bind the drug. Drugs in plasma bind principally to albumin or alpha-1-acid glycoprotein, and the concentration of these proteins in plasma can vary both between and within species ( Table 5 ). While plasma proteins exhibit structural homology between species, there are differences that may play a role in their ability to bind xenobiotics (17, 35) . Indeed, the unbound fraction of MK-571 (a leukotriene receptor antagonist) in plasma was found to vary 8-fold depending on the species and was associated with structural differences in the binding site for MK-571 on albumin (38) . The influence of interspecies differences in protein binding on pharmacokinetics can be profound. For alendronate, a 100-fold greater fraction unbound in dogs than rats nearly compensated for a 30-fold higher intrinsic clearance in rats (36) . While differences in the extent of protein binding can be large, even small differences can be of significance for drugs that are highly protein bound. For such drugs, subtle changes in the fraction bound can translate to large changes in the unbound concentration. Interindividual variability in protein binding in dogs has reported with some commonly used drugs (lidocaine, propranol). The binding of these drugs to alpha-1-acid glycoprotein was found to show high inter-and intra-individual variability and (4) correlated well with the amount of this protein in plasma. In the same study, drugs that bound to albumin had a lower degree of interindividual variability in binding, presumably due to the greater consistency in individual albumin concentrations. Such variability has also been noted in humans. It should also be noted that inflammatory processes, as might be experienced in a toxicologic study, can affect the concentrations of plasma proteins and their capacity to bind xenobiotics (16) . While it is not yet possible to make an a priori prediction of the degree of protein binding in dogs, or any other species, in vitro methods have allowed comparisons between species and provided substantial improvements in the correlation of the pharmacokinetics and pharmacodynamics between species. In addition to protein binding, physiologic volumes can affect the distribution of drugs. These physiologic volumes include plasma volume, extracellular and intracellular fluid volume, and adipose volume. For example, a drug avidly bound to albumin would have a volume of distribution similar to the extracellular fluid volume. Plasma volume in most species is proportional to body weight and constitutes approximately 3-5 ml/kg of body weight (14) . In the dog, plasma volume is at the higher end of that range (∼5 ml/kg) with man being slightly lower (∼4.3 ml/kg) and the rat even lower (∼3 ml/kg). Extracellular fluid volume is generally 20-30% of body weight in humans and in species used for toxicologic evaluation. Approximately 30-50% of the body weight in animals is comprised of intracellular fluid. Rabbits and monkeys have been reported to have intracellular water proportions on the upper end of the range (∼45%), yet rats, mice, dogs and humans occupy the lower range (30-40%) (14) . Lipid soluble drugs can distribute into adipose tissue, resulting in an increase in volume of distribution. Dogs and humans tend to have a higher proportion of body fat than rodents (∼7% in rodents, 15% in dogs, 20% in humans) (7) . Although fluid composition and adipose volume can play an important role in the distribution of drugs, it is important to realize that the volume of distribution of drugs is a complex interplay of physiologic volumes, tissue perfusion, and drug affinity for biological materials. As such, species differences in physiologic volumes should be used as a reference since other factors affecting volume of distribution may have a greater role in determining the overall volume of distribution.
DISCUSSION
A goal in using the dog for pharmacokinetic and toxicokinetic studies is to determine the relationship between the response obtained in dogs with that of other species. Because of its size, ease in sampling, and a well-understood physiology with similarities to humans, the dog has become and will continue to be a valuable species in the characterization and prediction of toxicity. The preceding discussion suggests that the dog has characteristics that are quite similar to those of other species and may allow for relatively direct comparisons (eg, glomerular filtration, gastric pH). Other physiologic characteristics unique to the dog can affect pharmacokinetics, making extrapolations between canines and other species unreliable. These unique characteristics can include differences in gastrointestinal function (gastric pH, gastric motility, and intestinal permeability), hepatic metabolism (N-acetylation, CYP450 substrate specificity), and plasma protein binding. Physiologic differences affecting pharmacokinetics constitute only one part of the equation linking xenobiotic administration with toxicity and such species differences can not always predict toxicologic sensitivity. Eberhart et al (19) found no correlation between digitoxin toxicity and digitoxin metabolism. Examples such as 2,3,7,8tetrachlorodibenzo-p-dioxin (dioxin, TCDD) (34), albuterol (49) , and minoxidil (42) , where pharmacokinetic equivalence between species does not confer equivalent pharmacologic activity, remind us that the complexities of the pharmacodynamic response need also be considered when attempting to predict toxicity in humans. Continued study of the pharmacokinetic processes, especially hepatic metabolism, in the commonly used laboratory species will improve our understanding of the similarities and differences that exist between dogs and other species and allow for better use of all species in making extrapolations of pharmacokinetics and toxicity.
